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We developed a new enzyme immunoassay (rpEIA) for use in determining the seroprevalence of chancroid.
Three highly conserved outer membrane proteins from Haemophilus ducreyi strain 35000 were cloned, overex-
pressed, and purified from Escherichia coli for use as antigens in the rpEIA. Serum specimens from patients
with and without chancroid were assayed to determine optimum sensitivity and specificity and to establish
cutoff values. On the basis of these data, rpEIA was found to be both sensitive and specific when used to test
a variety of serum specimens from patients with genital ulcers and urethritis and from healthy blood donors.
The sexually transmitted disease (STD) chancroid is caused
by Haemophilus ducreyi. H. ducreyi is a fastidious, slow-growing
gram-negative rod, which is known for its inability to synthesize
heme. Recent reviews of chancroid and H. ducreyi are available
(1, 21, 37). The incubation period for chancroid is between 4
and 7 days, when a small inflammatory papule or pustule con-
taining polymorphonuclear leukocytes may be seen. The pus-
tule soon ruptures, resulting in the loss of the epidermis, ex-
posure of the dermis, and formation of an ulcer containing
large numbers of organisms and inflammatory cells. Noticeably
absent is the dissemination of H. ducreyi, which may be due, in
part, to the lowered optimum growth temperature of H. du-
creyi, 33°C. This may explain its predilection for the skin.
Recent epidemiologic evidence from Africa clearly demon-
strates that chancroid is a risk factor for the spread of human
immunodeficiency virus (HIV) among heterosexuals (13, 14,
25), and several biological factors have been proposed to ac-
count for this. The ulcers of chancroid contain CD41 T cells,
and the virus has been isolated from chancroidal ulcers (17,
26), establishing these lesions as a portal of entry for HIV.
HIV-infected patients may also have greater numbers of ulcers
than non-HIV-infected patients. The semen from HIV-posi-
tive patients coinfected with chancroid contains higher levels
of HIV than semen from HIV-positive patients without chan-
croid (4). The resolution of treated chancroid lesions is pro-
longed in HIV-infected patients relative to the resolution of
those in HIV-uninfected patients (4). Thus, antibiotic-treated
HIV-infected patients with chancroid may be infectious for a
longer period of time for both etiologic agents. Taken to-
gether, all of these factors may contribute to the observed
cotransmission and prevalence of these two diseases in sub-
Saharan Africa (29); the term “infectious synergy” was coined
to describe this phenomenon (38).
The clinical diagnosis of chancroid is inaccurate (6, 33). In
addition, isolation of H. ducreyi from ulcer specimens is insen-
sitive (21). However, the detection of H. ducreyi DNA in ulcer
specimens by PCR has been shown to be significantly more
sensitive than detection by culture (16, 39). Unfortunately,
neither of these methods is readily available in areas of the
world where chancroid is endemic, such as Africa and Asia.
Several studies have used enzyme immunoassays (EIA) that
employ complex antigens to determine the seroprevalence of
chancroid in different populations (2, 8, 24, 30). In some of
these studies, cross-reacting antibodies present in serum spec-
imens from control patients made interpretation of the results
difficult (3, 28) and led to the requirement for adsorbing the
serum to remove these cross-reactive antibodies (adEIA). To
circumvent this problem, we have expressed the genes encod-
ing three outer membrane proteins of H. ducreyi strain 35000
and have purified the proteins to use them as antigens. Serum
specimens from patients with chancroid, other genital ulcer-
ative diseases (GUD) (including possible syphilis), and urethri-
tis and specimens from healthy blood donors in the United
States were tested for the presence of antibodies to these three
proteins using an EIA. We have termed this method rpEIA.
The recombinant proteins used in this study were the hemo-
globin receptor (HgbA) (9, 10), the heme receptor (TdhA)
(34), and the H. ducreyi D15 homolog (D15) (11, 18; K.
Thomas, B. Olsen, C. E. Thomas, and C. Elkins, unpublished
data). Antibodies to the three outer membrane proteins were
detected in serum specimens from all groups, but the preva-
lence was highest in specimens from patients with chancroid.
To date, no reliable serologic test which can differentiate be-
tween persons who have had chancroid and those who have not
exists. The results presented in this study suggest the possibility
that these purified recombinant proteins or other as yet unde-
scribed proteins may be useful for studies on the seropreva-
lence of chancroid.
MATERIALS AND METHODS
Strains and media. Bacterial strains used in this study are shown in Table 1.
For routine growth, H. ducreyi was maintained on chocolate agar plates (9).
Large-volume cultures of H. ducreyi and outer membrane isolation were per-
formed as previously described (9).
Escherichia coli strains were maintained on Luria-Bertani agar plates with
antibiotic selection where appropriate. Antibiotics were used at the following
concentrations for E. coli: ampicillin, 100 mg/ml; chloramphenicol, 30 mg/ml;
kanamycin, 30 mg/ml.
Construction of plasmids for expression of H. ducreyi outer membrane pro-
teins. Previously, it had been shown that high-level expression of gonococcal
outer membrane protein I (Por) was possible without toxicity when the por gene
lacking a leader sequence was cloned behind a T7-inducible promoter (27).
Expression of Por without a leader sequence resulted in the accumulation of
large quantities of protein in cytoplasmic inclusion bodies. A similar strategy was
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used to construct recombinant clones expressing the full-length, mature H. du-
creyi genes for HgbA, TdhA, and D15.
In the first step, each gene was amplified by PCR using the primers shown in
Table 2. These primers were designed with unique restriction sites for in-frame
fusion to the coding sequence for the hexahistidine leader of the expression
plasmid pET30a; the first amino acid of each H. ducreyi sequence was the N
terminus of the mature protein. PCR products were ligated into plasmid pCRII
and transformed into E. coli DH5aMCR. White colonies were analyzed by
restriction, and at least four containing the appropriately sized insert were
selected. Inserts were removed following digestion with the appropriate restric-
tion endonucleases and ligated into pET30a plasmids that had been cut with the
same enzymes (Table 2). After transformation into E. coli [BL21(DE3) pLysS or
Nova Blue (DE3)] and induction of recombinant protein synthesis with isopro-
pyl-1-thio-b-D-galactopyranoside (IPTG), several transformants were analyzed
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
Western blotting. These blots were probed with individual affinity-purified anti-
peptide sera to identify clones expressing the full-length product (9, 34; Thomas
et al., unpublished data).
Expression and purification of recombinant H. ducreyi outer membrane pro-
teins. Gene expression was induced by the method of Qi et al. (27). Briefly,
1-liter Luria-Bertani broth cultures were grown to an optical density at 600 nm
(OD600) of 0.5 and IPTG was added to 2 mM. After 30 min, rifampin (200 mg/ml)
was added, and incubation continued for two additional hours. Cells were har-
vested by centrifugation, and the inclusion bodies containing the recombinant
proteins were isolated as previously described (27) with the following modifica-
tions. The cell pellet was resuspended into 20 ml of 10 mM HEPES (pH 7.4) and
frozen. After being thawed, the cells were ruptured by passage through a French
press twice and then centrifuged at 10,000 3 g for 20 min. The resulting pellet
containing the inclusion bodies was resuspended in binding buffer (Novagen) and
centrifuged several times until the orange color of the pellet (residual rifampin)
was removed. The recombinant protein, which was the predominant protein in
the inclusion bodies (generally .90% pure) was further purified on Ni chelate
columns under denaturing conditions (6 M urea) as described by Novagen.
Following purification, urea was removed by gradual dialysis at 4°C to a concen-
tration of 2 M. Zwittergent 3,14 was then added to the retentate to 5%, and
dialysis was continued to remove the urea and putatively renature the proteins.
During each step of the procedure, phenylmethylsulfonyl fluoride (2 mM) was
added, and the protein was kept at 4°C.
Miscellaneous procedures. SDS-PAGE and Western blotting (immunoblot-
ting) were performed as previously described (9). The antisera used were affin-
ity-purified antipeptide sera to HgbA, TdhA, and D15 (9, 34; Thomas et al.,
unpublished data).
Specimens. A total of 330 serum specimens were obtained and stored at
270°C until tested. Serum specimens from STD clinic patients residing in areas
of high chancroid endemicity in South Africa were obtained from Ronald C.
Ballard (South African Institute for Medical Research, Johannesburg, South
Africa). These specimens were from (i) patients with PCR-confirmed chancroid
(n 5 40), (ii) patients with genital ulcers due to syphilis or genital herpes as
determined by PCR (n 5 29), and (iii) patients with urethritis (n 5 126) of whom
52% were HIV infected. All serum specimens were initially obtained for routine
diagnostic purposes from men presenting to STD clinics in Carletonville,
Durban, and Johannesburg, South Africa, between October 1993 and January
1994. Serum specimens (n 5 45) used as negative controls were obtained from
healthy blood donors in Atlanta, Georgia. Additional serum specimens consist-
ing of 45 Venereal Disease Research Laboratory (VDRL)-positive and 45
VDRL-negative sera were selected from among those submitted to the Georgia
State Health Department for syphilis serology.
EIA. (i) rpEIA. Ni-nitrilotriacetic acid HisSorb plates (Qiagen, Santa Clarita,
Calif.) were selected after evaluating various microtiter plates from several
manufacturers. Wells were coated with the recombinant H. ducreyi proteins
according to the manufacturer’s instructions. Each recombinant protein was
diluted in coating buffer (phosphate-buffered saline [PBS], pH 7.4, containing 1
M urea) to a concentration of 1 mg/ml, and 100 ml of the diluted protein was
added to each well. After incubation for 2 h at room temperature, wells were
washed three times with PBS, pH 7.4, containing 0.1% (vol/vol) Tween 20 (plate
wash buffer). Serum specimens were diluted 1:200 in PBS, pH 7.4, containing
0.1% (vol/vol) Tween 20 and 1% (vol/vol) fetal bovine serum; 100 ml was added
to each of two wells. Plates were incubated for 1 h at room temperature and then
washed three times with plate wash buffer. One hundred microliters of a 1:1,000
dilution of horseradish peroxidase-conjugated goat anti-human immunoglobulin
G (IgG) (EIA grade; Bio-Rad Laboratories, Hercules, Calif.) was added to each
well. Bound conjugate was detected spectrophotometrically at 405 nm after the
addition of 100 ml ABTS (2,29-azinobis(3-ethylbenzthiazolinesulfonic acid) in
accordance with the manufacturer’s instructions (1 mg/ml in ABTS buffer solu-
tion) (Calbiochem, La Jolla, Calif.) and incubation for 15 min at room temper-
ature. EIA were optimized by the use of receiver operator characteristic (ROC)
TABLE 1. Bacterial strains and plasmids
Strain or plasmid Relevant genotype or phenotype Source
Strains
E. coli K-12
DH5aMCR recA gyrB Bethesda Research Laboratories
BL21(DE3) pLysS F2 ompT hsDs(rBmB
2) gal dcm(DE3) pLysS (Cmr) Novagen




H. ducreyi 35000 Wild type Stanley Spinolaa
Plasmids
pET30a T7 expression vector; Kanr Novagen
pUNCH 671 tdhA; in pET30a This work
pUNCH 672 hgbA; in pET30a This work
pUNCH 1235 D15; in pET30a This work
pCRII PCR cloning vector; Kanr Ampr In vitrogen
a Indiana University. Originally obtained from William Schalla, Centers for Disease Control and Prevention.
TABLE 2. Primers used for PCR
Primer Sequencea Size of PCR product (bp)(length of protein product [amino acids])b
Restriction
site
HgbA 59 CCGGATCCGAAAGCAATATGCAAACA 2,868 (992) BamHI
HgbA 39 GCGGCCGCTTAGAAAGTGATCTCTGC NotI
TdhA 59 GATGGATCCGAGGATAATCCCAAAAAT 2,180 (780) BamHI
TdhA 39 GCGGCCGCGTCGTTTTATGAAGTCAA NotI
D15 59 GGATCCGAATTCGCACCATTTGTAGTAAAAGAT 2,361 (819) BamHI
D15 39 CAGTTGGCAGCACATTCTAATTCGAACGCCGGCG NotI
a H. ducreyi sequence is shown in boldface, and restriction sites are underlined.
b Each protein product includes an N-terminal hexahistidine leader encoded by the vector. The vector leader sequence is fused to the first mature amino acid of each
H. ducreyi protein, and all three proteins end with the native terminal phenylalanine. The vector leader adds 40, 40, and 42 amino acids to the mature protein sequences
of H. ducreyi HgbA, TdhA, and D15, respectively.
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curves (20, 39), which were constructed by plotting the sensitivity versus the
false-positive rate at increments of 0.05 sensitivity. A cutoff value for each
antigen-specific assay was selected based on optimal performance.
(ii) adEIA. The adEIA was performed as described previously (5).
RESULTS
Cloning, expression, and purification of recombinant H. du-
creyi outer membrane proteins. The coding sequences for ma-
ture forms of HgbA, TdhA, and D15 were amplified by PCR
and cloned into pCRII using the primers shown in Table 2.
Inserts were directionally subcloned in frame into the pET30a
expression vector, and E. coli strains containing the l lysogen
DE3 were transformed. Induction of gene expression in E. coli
with IPTG followed by inhibition of RNA polymerase with
rifampin (27) resulted in the expression of each recombinant
protein such that it was the predominant protein observed on
SDS-PAGE gels of whole-cell extracts (data not shown). In-
clusion bodies containing the recombinant protein were iso-
lated and purified under denaturing conditions by metal che-
late chromatography. SDS-PAGE followed by staining with
Coomassie blue was used to compare the relative mobilities of
native H. ducreyi outer membrane proteins with those of the
purified recombinant proteins (Fig. 1). SDS-PAGE was also
used to assess the relative purity of the recombinant proteins.
To confirm that the purified recombinant proteins contained
peptide sequences derived from the N-terminal Edman degra-
dation amino acid sequence data (HgbA and D15) or the
deduced amino acid sequence (TdhA) of these proteins, West-
ern blots were probed with the relevant affinity-purified IgG
from rabbits which had been immunized with synthetic pep-
tides. The results (Fig. 1) demonstrate that the affinity-purified
IgG recognized both the native and recombinant forms of each
protein. Several smaller immunoreactive bands were also ob-
served in preparations of purified recombinant proteins. These
bands could be the result of proteolysis, alternative start sites
for transcription, or premature termination (transcription or
translation) due to the high AT content of H. ducreyi DNA.
These immunoreactive bands were not observed in prepara-
tions prepared from E. coli containing pET30a alone, suggest-
ing that they were not contaminants. Others (27) have ob-
served these smaller proteins in similar preparations from a
variety of recombinant proteins. The H. ducreyi outer mem-
brane proteins HgbA, TdhA, and D15 are very basic and rel-
atively large. These proteins are made still more basic by the
addition of the hexahistidine leader sequence (10, 26, 27).
Examination of SDS-PAGE gels stained with Coomassie blue
after electrotransfer to nitrocellulose revealed that the major-
ity of the recombinant protein (especially recombinant HgbA
[rHgbA]) remained in the gel, whereas the smaller proteins
were transferred to the nitrocellulose (data not shown). Thus,
the smaller proteins are overrepresented in the Western blots
(compare left and right panels in Fig. 1).
Optimization of EIA. Serum specimens from patients with
PCR-confirmed chancroid (n 5 40) and from healthy U.S.
blood donors (n 5 45) were employed to optimize the perfor-
mance characteristics of the assays. Healthy U.S. blood donor
sera were used as negative controls instead of South African
PCR-negative sera because chancroid is highly endemic in
South Africa compared to the United States. A negative PCR
result indicates only the lack of current chancroid infection and
does not indicate if prior infection had occurred in an individ-
ual. Since the possibility of prior chancroid infection in South
African individuals was relatively high compared to that for
U.S. individuals, we concluded that the use of U.S. sera was
appropriate and proper. Using ROC plots, cutoff values which
maximized the sensitivity and specificity of each recombinant
antigen-specific assay were selected. The ratios of the mean
OD405 of the serum specimens from patients with chancroid to
the mean OD405 of the serum specimens from healthy blood
donors were 3.16, 2.21, and 3.00 for HgbA, TdhA, and D15,
respectively. The cutoff values (OD405) for each antigen-spe-
cific assay, based on optimal performance, were 0.30 (HgbA),
0.40 (TdhA), and 0.30 (D15). The OD values for the 40 serum
specimens from patients with chancroid and the 45 serum
specimens from healthy blood donors are shown in Fig. 2.
Serum specimens from 35 of 40 (88%) patients with chancroid
had antibodies to all three recombinant antigens. Serum spec-
imens that exhibited a high OD reading against one antigen
consistently had high OD readings against the other two anti-
gens. The five remaining chancroid patients had antibodies to
only two of the recombinant antigens (three patients had an-
tibodies to TdhA and D15, and two patients had antibodies to
FIG. 1. (Left panel) SDS-PAGE and Coomassie staining of H. ducreyi outer membrane proteins and purified recombinant proteins. H. ducreyi strain 35000 was
grown under heme-limiting conditions to induce synthesis of HgbA and TdhA. Recombinant His-tagged proteins were purified from E. coli as described in the text.
Lanes: OMP, H. ducreyi outer membrane proteins (30 mg); rHgbA, rTdhA, rD15, purified recombinant proteins (2 mg each). Note the larger sizes of the hexahistidine
leader-containing recombinant proteins compared to their respective native proteins. (Right panel) Western blots of H. ducreyi outer membrane proteins and
recombinant proteins. Blots A, B, and C were probed with affinity-purified antipeptide IgG to HgbA, TdhA, or D15, respectively. In blot A, only 5 mg of outer membrane
protein was loaded to visualize the abundant HgbA protein. In blots B and C, 30 mg of outer membrane protein was loaded to visualize the less abundant TdhA and
D15 proteins. Each lane of recombinant protein contained 200 to 400 ng of protein.
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HgbA and D15). All of the patients with PCR-confirmed chan-
croid had antibody levels to D15 that were above the cutoff;
however, 4 of 40 (10%) and 3 of 40 (7.5%) lacked antibodies
to HgbA and TdhA, respectively. The prevalence of antibodies
to these recombinant proteins was relatively uncommon
among healthy blood donors; only one individual had antibod-
ies to D15 while three and four donors, respectively, had an-
tibodies to HgbA and TdhA. Thus, to enhance the specificity of
these assays, only seroreactivity to HgbA and D15 was used for
some comparisons (Table 3).
The mean OD405 for each antigen using serum specimens
from patients with PCR-confirmed chancroid was significantly
higher (P , 0.0001) than the mean OD405 for serum specimens
from any of the other patient groups examined (Table 4). Thus,
the mean OD was related to the prevalence and likelihood of
having chancroid.
Serum specimens from South African GUD patients (n 5
29) with PCR-confirmed genital herpes or syphilis were also
tested to determine the prevalence of antibodies to H. ducreyi
HgbA and D15; 19 of 29 (66%) of these patients were also
infected with HIV (Table 3). Among these patients, 11 of 29
(38%) had antibodies to at least one of the antigens, and of
these, 9 of 11 had antibodies to HgbA (5 had antibodies to
HgbA and D15, and 4 had antibodies to HgbA) and 2 of 11 had
antibodies to only D15. There was no significant effect of HIV
infection status on seroreactivity to these antigens (data not
shown). Compared to the results obtained from GUD patients
with chancroid, the mean OD405 of the serum specimens from
those with genital herpes or syphilis was 40 to 50% lower for
each antigen (Table 4). Among all GUD patients, rpEIA for
the presence of antibodies to HgbA and D15 had a sensitivity
of 100% and a specificity of 62% compared with multiplex
PCR (M-PCR) for H. ducreyi.
Serum specimens from South African STD clinic patients
with urethritis or GUD were also tested for the presence of
antibodies to HgbA and D15 (Table 3). The mean OD405s for
the antigens were similar and were less than the mean OD405s
for patients with chancroid or for those with genital herpes or
syphilis (Table 4). There was no significant effect of HIV in-
fection status on the seroreactivity to these antigens. Most of
the patients with urethritis 84 of 126 (67%) lacked antibodies
to these proteins as measured by EIA. Of those with antibod-
ies, 24 of 126 (19%) had antibodies to HgbA and D15; 10 of
126 (7.9%) had antibodies to HgbA, and 7 of 126 (5.6%) had
antibodies to D15.
Chancroid is endemic in Georgia and is responsible for a
small percentage of GUD in patients attending STD clinics
(36). Thus, serum specimens randomly selected from among
those submitted to the Georgia State Health Department lab-
oratory for syphilis serology (45 VDRL positive and 45 VDRL
negative) were tested for the presence of antibodies to HgbA
and D15. The results (Table 3) showed that patients with
VDRL-positive sera were significantly more likely to have an-
tibodies to HgbA and D15 than those with VDRL-negative
sera (12 of 45 [26%] versus 5 of 45 [11%]; P ,0.001). Overall,
17 of 90 (18.9%) of these randomly selected specimens that
were submitted for syphilis serology had antibodies to either
HgbA or D15.
FIG. 2. Serum specimens from 40 patients with lesions positive for H. ducreyi by M-PCR (open circles) and 45 normal human sera (solid circles) were tested in
rpEIA using rHgbA, rTdhA, and rD15 protein antigens. O.D., OD405. The cutoff value for each antigen was established by ROC analysis (data not shown).
TABLE 3. Prevalence of antibodies to H. ducreyi HgbA and D15 among South African and U.S. populations
with different levels of risk for chancroid
Presence of
antibody to:
No. (%) of specimens positive or antibody in:



















1 1 37 (93) 5 (17) 13 (20) 11 (19) 2 (4) 3 (7) 1 (2)
1 2 0 4 (14) 4 (6) 6 (10) 2 (4) 1 (2) 0
2 1 3 (7) 2 (7) 3 (5) 4 (7) 8 (18) 1 (2) 0
2 2 0 18 (62) 46 (70) 38 (64) 33 (73) 40 (89) 44 (98)
a Hd, patients with PCR-confirmed chancroid.
b Other GUD, patients with PCR-confirmed genital herpes or syphilis.
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Comparison of rpEIA and adEIA. Serum specimens positive
for H. ducreyi (n 5 40) and for herpes simplex virus or Trepo-
nema pallidum (n 5 29) by PCR from patients who attended
STD clinics in South Africa were assayed by both the rpEIA
and adEIA. A comparison of the assay results is shown in Fig.
3A and B. There was little correlation between the results of
these assays when serum specimens from patients with chan-
croid were used. The correlation coefficients (r) were 0.07,
0.24, and 0.25 for HgbA, TdhA, and D15, respectively. The
rpEIA was more sensitive than the adEIA in identifying GUD
patients with chancroid. However, among patients with chan-
croid, the OD from the adEIA was generally greater than that
from the rpEIA. This difference is likely due to the detection of
antibodies to multiple antigens. In contrast, the rpEIA de-
tected the presence of low levels of antibodies to HgbA, D15,
and TdhA in several specimens from South African patients
with genital herpes or syphilis. These antibodies may reflect
past infection with H. ducreyi. There was a higher, but not
significant, correlation between the two assays with specimens
from this group of African patients (r 5 0.66, 0.60, and 0.50 for
HgbA, TdhA, and D15, respectively).
DISCUSSION
In this study, we sought to develop an improved serological
assay (rpEIA) for use in seroprevalence studies of chancroid.
The adEIA, which has been used in most seroprevalence stud-
ies, is cumbersome and difficult to standardize, and its results
may be difficult to interpret. In the adEIA, serum specimens
are adsorbed with a mixture of antigens (sorbent) prepared
from a variety of related and unrelated bacterial species. Some
of the bacteria used as the sorbent (e.g., Haemophilus influen-
zae) have been recently shown to have certain genes encoding
FIG. 3. Correlation between adEIA and rpEIA. Forty M-PCR-positive (A) and 29 M-PCR-negative (B) specimens were subjected to adEIA or rpEIA.
TABLE 4. Mean OD values for antigen-specific rpEIA for serum
specimens from South African and U.S. patient populations
with different levels of risk for chancroid
Group
Mean OD405 6 SD for:
HgbA TdhA D15
South Africa
Chancroid (n 5 40) 0.61 6 0.26 0.64 6 0.24 0.51 6 0.18
Other (n 5 29) 0.34 6 0.16 0.34 6 0.16 0.27 6 0.11
Urethritis
HIV1 (n 5 66) 0.27 6 0.20 0.29 6 0.17 0.25 6 0.15
HIV2 (n 5 60) 0.28 6 0.18 0.27 6 0.14 0.24 6 0.12
United States
VDRL1 (n 5 45) 0.20 6 0.10 0.32 6 0.18 0.25 6 0.14
VDRL2 (n 5 45) 0.21 6 0.19 0.23 6 0.17 0.24 6 0.20
Blood donors (n 5 45) 0.19 6 0.06 0.29 6 0.09 0.17 6 0.05
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outer membrane proteins that are similar in structure and
function to those of H. ducreyi. These genes from other bac-
teria encode proteins related structurally to HgbA (19, 22),
TdhA (12), D15, OmpA1 and OmpA2 (23), P6 lipoprotein (7,
31), and the LspA proteins (32) from H. ducreyi. Undoubtedly,
additional H. ducreyi antigens whose homologs are also present
in other members of the Pasteurellaceae will be identified.
Thus, the adsorption step may actually remove important an-
tibodies. In addition, the antigen used in the adEIA is a crude
extract of H. ducreyi. Since microtiter plate wells have a limited
binding capacity, the amount of each antigen bound in a crude
extract is small relative to the amount bound using a homog-
enous protein antigen. In addition, two of the three proteins
used in rpEIA are heme regulated (HgbA and TdhA). Since
the adEIA whole-cell antigen used was prepared from H. du-
creyi grown under high-heme conditions, HgbA and TdhA are
either not present or are present in reduced amounts. It is
likely that a combination of these factors was responsible for
the differences observed when rpEIA and adEIA results were
compared (Fig. 3). The rpEIA detected a higher proportion of
patients with current chancroid and a higher proportion of
patients who were likely to have had chancroid in the past.
Based on a limited number of published studies, the sensi-
tivity of the rpEIA was greater than that of either the adEIA or
the lipooligosaccharide (LOS) EIA among patients with M-
PCR-confirmed chancroid in Mississippi (53 versus 48%, re-
spectively) (5) or in Dakar, Senegal (71 versus 59%, respec-
tively) (35). Differences in the apparent sensitivity and
specificity may be due, in part, to different patient populations,
the prevalence of chancroid in those populations, and the
availability of health care. Likewise, the relatively low specific-
ity of the rpEIA may reflect the high prevalence of prior
chancroid infection among STD clinic patients in South Africa.
Relatively high specificities of adEIA (71%) and LOS EIA
(89%) were observed among GUD patients from Mississippi,
where previous chancroid incidence was low. The relatively
high LOS EIA sensitivity may be due to a relatively short
half-life for anti-LOS IgG.
The rpEIA is a method that can be standardized and used to
directly compare populations from different geographic areas
and risk groups. Moreover, the use of purified recombinant
protein antigens offers several technical advantages. Tens of
milligrams of recombinant protein can be obtained from 1 liter
of bacterial culture. We have found that 1 mg of the protein is
sufficient to coat 5,000 wells. Thus, a single laboratory can
serve as a repository for purified proteins or precoated micro-
titer plates for use by distant laboratories. If additional anti-
gens are later found to be useful, their addition to this assay
would represent a trivial modification.
Results obtained using serum specimens from patient pop-
ulations residing in areas of high and low chancroid endemicity
provide strong evidence for the high sensitivity and specificity
of the rpEIA. In this limited study, the antibody response to
HgbA and D15 was found to correlate with the risk for chan-
croid (Tables 3 and 4). Although H. influenzae possesses ho-
mologs of HgbA, TdhA, and D15 and although humans are
often exposed to this bacterium, we did not observe significant
reactivity to these proteins among a group of healthy blood
donors. There are several explanations for this finding. Using a
variety of polyclonal antisera, we were unable to detect signif-
icant cross-reactivity between the H. ducreyi HgbA and its
homolog in H. influenzae (9, 15; unpublished data). In addition,
polyclonal antisera to H. influenzae D15 reacted poorly with H.
ducreyi D15 (unpublished data). Alternatively, antibodies to H.
influenzae proteins are acquired during childhood and are be-
low detectable levels in most adults. H. ducreyi TdhA is poorly
expressed in vitro (34). However, significant levels of antibody
to TdhA are present in the serum of patients with chancroid,
suggesting that this protein is antigenic and expressed in vivo.
The low levels of antibodies to TdhA that were found in serum
from a few healthy individuals suggests that this antigen may be
less useful in discriminating between individuals who were
previously infected and those who were never infected with H.
ducreyi.
The proportion of patients with antibodies to HgbA and
D15 was related to the prevalence as well as the risk for
chancroid. All of the men who presented to STD clinics in
South Africa with chancroid had antibody levels to HgbA or
D15 that were above the cutoff value. In contrast, only 2% (1
of 45) of healthy blood donors from Atlanta, Georgia, had
antibodies to these proteins. During the same time period,
South African men presenting to these STD clinics with genital
herpes, primary syphilis, or urethritis had a 30 to 40% preva-
lence of antibodies to HgbA and D15. The level of antibodies
in this group of patients was less than that observed in patients
with chancroid, suggesting that chanroid may have been ac-
quired at an earlier date. Serum specimens from individuals in
the United States were divided into groups based on their risk
for GUD. Among serum specimens submitted to the Georgia
State Public Health Laboratory for syphilis serology, those that
were VDRL positive had a 2.5-fold higher prevalence of anti-
bodies than those that were VDRL negative. Overall, individ-
uals with VDRL-negative serum specimens were considered to
be at medium risk for GUD, as an undetermined number of
these specimens were obtained for legal screening require-
ments and were from individuals who were likely to be at low
risk for syphilis.
While the presence of antibodies to HgbA, TdhA, and D15
is strongly correlated with current infection with H. ducreyi, we
wish to emphasize that this test was designed to be used for
seroprevalence studies and not for the diagnosis of current
infection. The limitations of this study are that we were unable
to obtain a reliable history of prior chancroid from these pa-
tients and thus can only assign a relative risk for prior chan-
croid. Additionally, studies are needed to determine the per-
sistence of these antibodies after treatment and the effect of
reinfection on antibody level.
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